G
Gloria Vigliani
Researcher at Biogen Idec
Publications - 10
Citations - 2790
Gloria Vigliani is an academic researcher from Biogen Idec. The author has contributed to research in topics: Daptomycin & Vancomycin. The author has an hindex of 9, co-authored 10 publications receiving 2592 citations. Previous affiliations of Gloria Vigliani include Cubist Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Vance G. Fowler,Helen W. Boucher,G. Ralph Corey,Elias Abrutyn,Adolf W. Karchmer,Mark E. Rupp,Donald P. Levine,Henry F. Chambers,Francis P. Tally,Gloria Vigliani,Christopher H. Cabell,Arthur Stanley Link,Ignace DeMeyer,Scott G. Filler,Marcus J. Zervos,Paul P. Cook,Jeffrey Parsonnet,Jack M. Bernstein,Connie S. Price,Graeme N. Forrest,Gerd Fätkenheuer,Marcelo Gareca,Susan J. Rehm,Hans Reinhardt Brodt,Alan D. Tice,Sara E. Cosgrove +25 more
TL;DR: Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis and met prespecified criteria for the noninferiority of daptomecin.
Journal ArticleDOI
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu,Jerry S. Powell,Margaret V. Ragni,Pratima Chowdary,Neil C. Josephson,Ingrid Pabinger,H. Hanabusa,Naresh Gupta,Roshni Kulkarni,Patrick F. Fogarty,David J. Perry,Amy D. Shapiro,K. John Pasi,Shashikant Apte,Ivan Nestorov,Haiyan Jiang,Shuanglian Li,Srividya Neelakantan,Lynda M. Cristiano,Jaya Goyal,Jurg M. Sommer,Jennifer A. Dumont,Nigel Dodd,Karen Nugent,Gloria Vigliani,Alvin Luk,Aoife Brennan,Glenn F. Pierce +27 more
TL;DR: In this paper, the authors evaluated the safety, efficacy, and pharmacokinetics of recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males aged ≥12 years with severe hemophilia A.
Journal ArticleDOI
Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy Volunteers
TL;DR: Daptomycin was well tolerated in subjects dosed with up to 12 mg/kg intravenously for 14 days and may be considered in further studies to evaluate the safety and efficacy of daptomyin in difficult-to-treat infections.
Journal ArticleDOI
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Jerry S. Powell,K. John Pasi,Margaret V. Ragni,Margareth C. Ozelo,Leonard A. Valentino,Johnny Mahlangu,Neil C. Josephson,D. J. Perry,Marilyn J. Manco-Johnson,Shashikant Apte,Ross I. Baker,Godfrey Chi-Fung Chan,Nicolas Novitzky,Raymond S.M. Wong,Snejana Krassova,G. Allen,Haiyan Jiang,Alison Innes,Shuanglian Li,Lynda M. Cristiano,Jaya Goyal,Jurg M. Sommer,Jennifer A. Dumont,Karen Nugent,Gloria Vigliani,Aoife Brennan,Alvin Luk,Glenn F. Pierce +27 more
TL;DR: Prophylactic rFIXFc, administered every 1 to 2 weeks, resulted in low annualized bleeding rates in patients with hemophilia B, mostly consistent with those expected in the general population of patients withhemophilia.
Journal ArticleDOI
Initial Low-Dose Gentamicin for Staphylococcus aureus Bacteremia and Endocarditis Is Nephrotoxic
Sara E. Cosgrove,Gloria Vigliani,Marilyn Campion,Vance G. Fowler,Elias Abrutyn,G. Ralph Corey,Donald P. Levine,Mark E. Rupp,Henry F. Chambers,Adolf W. Karchmer,Helen W. Boucher +10 more
TL;DR: Initial low-dose gentamicin as part of therapy for S. aureus bacteremia and native valve infective endocarditis is nephrotoxic and should not be used routinely, given the minimal existing data supporting its benefit.